( NASDAQ-NMS:SVNT )

News from savient pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Dec 13, 2013, 12:07 ET Savient Receives Approval From Bankruptcy Court To Sell Substantially All Assets To Crealta Pharmaceuticals

 Savient Pharmaceuticals, Inc. (OTC: SVNTQ) ("Savient") announced today that it has received approval from the U.S. Bankruptcy Court for the...


Dec 11, 2013, 07:00 ET Savient Reaches Agreement To Sell Substantially All Assets To Crealta Pharmaceuticals

 Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) ("Savient") announced today that it has reached agreement on the terms of an acquisition...


Dec 10, 2013, 00:28 ET Savient Reaches Agreement On Use Of Cash Collateral

Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) ("Savient") announced today that an agreement in principle has been reached by and among Savient, the...


Oct 16, 2013, 16:51 ET Savient Receives Court Approval Of Key "First Day" Motions

Savient Pharmaceuticals, Inc. (NASDAQ: SVNT)("Savient") announced today the approval of its "first day" motions by the U.S. Bankruptcy Court for...


Oct 14, 2013, 19:46 ET Savient Pharmaceuticals Commences Voluntary Chapter 11 Proceeding; Seeks To Conduct Auction And Sale Under Section 363

Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) ("Savient") announced today that it has elected to file voluntary petitions under Chapter 11 of the...


Oct 08, 2013, 08:30 ET Savient Pharmaceuticals Announces Abstract Related To KRYSTEXXA® Accepted For Presentation At ASN Kidney Week 2013

 Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that an abstract related to KRYSTEXXA® (pegloticase) has been selected...


Oct 03, 2013, 16:35 ET Savient Announces Multiple Abstracts Related to KRYSTEXXA® to be Presented at the 2013 ACR/ARHP Annual Meeting

Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that several abstracts related to KRYSTEXXA® (pegloticase) have been...


Aug 14, 2013, 07:00 ET Savient Pharmaceuticals Reports Second Quarter 2013 Financial Results

 Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today reported financial results for the three and six-month periods ended June 30, 2013. ...


Jun 20, 2013, 16:05 ET Savient Pharmaceuticals Announces Formation of Office of the President

Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that it has formed an Office of the President, consisting of Richard Crowley, who will...


Jun 12, 2013, 08:00 ET Savient Pharmaceuticals to Present New KRYSTEXXA® Data at the 2013 European League Against Rheumatism (EULAR) Congress

 Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that ongoing KRYSTEXXA® (pegloticase) post-marketing surveillance data...


May 22, 2013, 13:38 ET Jim Belushi, Savient And CreakyJoints Team Up To Shift The Conversation About Gout

Jim Belushi, Savient Pharmaceuticals and patient advocacy group CreakyJoints have released a new online video to encourage candid discussion...


May 15, 2013, 07:00 ET Savient Pharmaceuticals Reports First Quarter 2013 Financial Results

 Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today reported financial results for the three months ended March 31, 2013.  Net sales of...


Mar 19, 2013, 07:00 ET Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2012 Financial Results

 Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today reported financial results for the three months and full year ended December 31,...


Feb 26, 2013, 08:30 ET Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2012 Financial Results Conference Call on Tuesday, March 19, 2013

 Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that the Company's fourth quarter and year-end 2012 financial results will be...


Feb 19, 2013, 08:30 ET Sobi and Savient Pharmaceuticals Announce Co-Promotion Agreement for Kineret® (anakinra) in the U.S.

 Sobi (STO: SOBI) and Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that they have entered into an agreement for the...


Jan 08, 2013, 11:42 ET Savient's KRYSTEXXA® (pegloticase) Receives European Commission Marketing Authorization for the Treatment of Certain Patients with Chronic Tophaceous Gout

Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) and its wholly owned subsidiary, Savient Pharma Ireland Ltd., today announced that the European...


Jan 08, 2013, 08:30 ET Savient Pharmaceuticals Announces the Election of Genzyme CEO Dr. David Meeker to Its Board of Directors

 Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that David Meeker, M.D., President and Chief Executive Officer of Genzyme, a...


Jan 04, 2013, 08:30 ET Savient Pharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare Conference

 Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that Lou Ferrari, President and Chief Executive Officer, will present at the 31st...


Dec 05, 2012, 08:30 ET Savient Announces the Election of Robert G. Savage to its Board of Directors

 Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that Robert (Bob) G. Savage has been elected to the Company's Board of Directors,...


Nov 13, 2012, 08:00 ET New Data Demonstrate KRYSTEXXA®-Treated Refractory Chronic Gout Patients Experienced Significantly Improved Health-Related Quality of Life

 Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced results from new post-hoc analyses of KRYSTEXXA® (pegloticase) pivotal Phase...


Nov 12, 2012, 08:00 ET New Data Published in Annals of the Rheumatic Diseases Confirm Long-Term Safety and Efficacy of KRYSTEXXA® for the Treatment of Refractory Chronic Gout

 Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that new data from an open-label extension (OLE) study published in the Annals of...


Nov 08, 2012, 07:00 ET Savient Pharmaceuticals Reports Third Quarter 2012 Financial Results

 Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today reported financial results for the three and nine months ended September 30, 2012, which...


Oct 25, 2012, 16:05 ET Savient Pharmaceuticals to Hold Third Quarter 2012 Financial Results Conference Call on Thursday, November 8, 2012

 Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that the Company's third quarter 2012 financial results will be released prior to...


Oct 19, 2012, 10:50 ET Savient Receives Positive CHMP Opinion for KRYSTEXXA® Approval in the EU

 Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) and its wholly owned subsidiary, Savient Pharma Ireland Limited, today announced that the...


Sep 26, 2012, 16:50 ET Savient Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that it has granted time-based restricted shares, and time-based and...